An energy‐based, mechanistic model of MAPK signaling is developed to describe the network rewiring responsible for adaptive (non‐genetic) and genetic resistance to RAF and MEK inhibitors in BRAF‐mutant cancers. The gene discussed is MAP2K7; the disease is cancer.